- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02442713
The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia
A Baseline Controlled Study With Fluvoxamine to Evaluate the Effect on Polysonogram in Depressed Patients With Insomnia
Major depressive disorder is associated with several sleep Polysomnograph (PSG) findings: (1) impaired sleep continuity; (2) non-REM (NREM) changes; and (3) enhanced rapid eye movement (REM) sleep. The first two patterns are common in other psychiatric disorders, while the REM pattern is very characteristic in depression, so the phase-advance theory was accepted by most of psychiatrists. Many researchers have focused on the biological rhythm to investigate the etiological and pathophysiology of depression, and they think depression can be cured if its sleep abnormality is ameliorated.
It is well known that most of antidepressants treat depression through 5-hydroxytryptamine (5-HT) neurons. 5-HT also affects the regulation of the sleep-wake cycle and the sleep microarchitecture. Many all-night PSG studies have shown tricyclic antidepressants can ameliorate the sleep architecture abnormality in depression by producing rapid suppression of REM sleep.
Compared to TCAs, SSRIs are generally less sedating because of its high selectivity for serotonin receptors. On the other hand, it is known that, although all of SSRIs mainly increase the extracellular serotonin level by inhibiting serotonin transport in the presynaptic neuron, each SSRI has its unique pharmacological characteristics. For example, it was reported by accumulating researches that the serum melatonin level increased markedly after ingestion of fluvoxamine. The mechanism behind this effect is unknown, but one possibility is increased melatonin synthesis, caused by effects on serotonin, which is a melatonin precursor. Another possibility is that fluvoxamine inhibits the metabolism of melatonin in the liver.
Thus, the property of fluvoxamine to increase serum melatonin level, or even recover the circadian rhythm of melatonin in depressed patients, might improve the clinical outcome by improving the sleep quality and quantity. By now, the changes of sleep architecture in fluvoxamine treatment were assessed by only three clinical trials, and their results were contradictive. This discrepancy might be due to the small sample size and different study design, such as clinical trial duration. Moreover, two of three researches applied home-based PSG assessment, which might have distorted the results of sleep architecture to some extent. Thus, the effects of fluvoxamine on sleep architecture need to be clarified by more clinical trials with standard PSG assessment.
Study Overview
Detailed Description
This study is aimed to evaluate the effect of fluvoxamine on polysomnographic (PSG) variables and clinical improvement in the treatment of depressive patients with insomnia.
This is an 8-week open-label study. All patients are required to meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) [48 criteria for MDD, single or recurrent type, with moderate-to-high level of illness severity, as evidenced by a 17-item Hamilton Rating Scale for Depression (HRSD) score >17 [49, 50]. Furthermore, these depressed patients should be suffering insomnia, which was determined by the total score of sleep disturbance factor in HRSD >3 (items 4, 5, and 6; score range, 0-6).
Before any procedure of the study, the patient would be explained in detail about the potential risk and benefit in this study with a signed informed consent form (ICF). Patients can discontinue the study at any time after informed consent. Also, this study should be approved by Independent Ethics Committee (IEC) of Guang Dong Mental Health Center and compliance with the content of the declaration of Helsinki.
After 7-day wash-out period and 2 nights PSG (the first night as adaptive and the second night as baseline), 30 depressive patients were administered by fluvoxamine as 50 mg/day in the 1st day. The dosage of fluvoxamine would be titrated during the 8-week treatment, and the maximum was lower than 300 mg/day. The primary endpoints were the changes of PSG variables from baseline to the 56th Day. The secondary endpoints were the changes of subjective sleep quality and clinical performance from baseline to the 56th Day. Their sleep quality was evaluated with Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI), and their clinical performance was evaluated with HRSD and Clinical Globe Impression (CGI).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bin Zhang, M.D&Ph.D
- Phone Number: 86-20-81888553
- Email: zhang73bin@hotmail.com
Study Locations
-
-
Guangdong
-
Guang Zhou, Guangdong, China, 510120
- Recruiting
- Guangdong Provincial Mental Health Institute
-
Contact:
- Bin Zhang, M.D&Ph.D
- Phone Number: 8620-81888553
- Email: zhang73bin@hotmail.com
-
Principal Investigator:
- Bin Zhang, M.D&Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For inclusion in the study patients must fulfil all of the following criteria:
- Male or female, ≥18 years and ≤65 years old
- Major depressive disorder patients with insomnia (diagnosed with DSM-IV, HRSD total score >17 and total score of sleep disturbance factor in HRSD (items 4, 5, and 6; score range, 0-6)>3)
- Patients who are able to understand and comply with the requirements of the study
- Provision of written informed consent
Exclusion Criteria:
Any of the following is regarded as a criterion for exclusion from the study:
- Any contraindication or caution of fluvoxamine according to Chinese label
- Any DSM-IV Axis I disorder, except for major depressive disorder
- Being currently treated or having been treated with fluvoxamine or other antidepressants within 4 weeks prior to entering the study
- Participation to this study or another trial within 4 weeks prior to entering the study
- Other sleeping disorder such as apnoea, Periodic Leg Movement in Sleep and narcolepsy
- Pregnancy or lactation
- Substance or alcohol dependence or any drug abuse.
- Other conditions at Investigator's discretion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fluvoxamine
fluvoxamine: 50-300mg/day
|
fluvoxamine: 50-300mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of sleep during Fluvoxamine treatment
Time Frame: 56 days
|
by comparing the percentages of Rapid Eye Movement (REM) on the 1st, 14th, 28th and 56th day.
|
56 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of Slow Wave sleep (SWS) during Fluvoxamine treatment
Time Frame: 56 days
|
by comparing the percentages of Slow Wave sleep (SWS) on the 1st, 14th, 28th and 56th day.
|
56 days
|
The change of sleep efficiency during Fluvoxamine treatment
Time Frame: 56 days
|
by comparing the sleep efficiency on the 1st, 14th, 28th and 56th day.
|
56 days
|
Clinical improvement during Fluvoxamine treatment
Time Frame: 56 days
|
by comparing scores of Hamilton Rating Scale for Depression (HRSD) on the 1st, 14th, 28th and 56th day.
|
56 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: 86-20-81888553 Zhang, M.D&Ph.D, Guang Dong Provincial Mental Health Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Depression
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluvoxamine
Other Study ID Numbers
- FLUVD002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on fluvoxamine
-
Guangdong Provincial People's HospitalCompletedObsessive Compulsive DisorderChina
-
Chulalongkorn UniversityWashington University School of Medicine; Mahidol University; Ramathibodi Hospital and other collaboratorsCompletedTreatment EfficacyThailand
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors, Excluding Breast CancerNetherlands, Switzerland, Denmark, United States
-
Sha'ar Menashe Mental Health CenterUnknownSCHIZOPHRENIA 1 (Disorder)Israel
-
Susanna Naggie, MDVanderbilt University Medical Center; National Center for Advancing Translational...Completed
-
Hadassah Medical OrganizationCompletedDrug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors
-
Solvay PharmaceuticalsCompleted
-
Lingjiang LiRecruitingDepressive Disorder | Melancholia | Endogenous DepressionChina
-
Susanna Naggie, MDVanderbilt University Medical Center; National Center for Advancing Translational...Completed